ClinicalTrials.gg
Active, not recruitingNCT03960840Updated Oct 29, 2026

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

A Phase 1/2 interventional study of Rapcabtagene autoleucel single agent and Ibrutinib in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 37 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Updated Oct 29, 2026Study completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
218
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 83
218 · median 44
Started
2019
with 6 others
Phase 1/2
7 of 83
1 open now
Primary completion
2027-06
later than 19 of 27 live
Registered
66th of 83
by date

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 7 that started in 2019, is one of 7 in phase 1/2, reaches primary completion later than 19 of the 27 other live ones, and was the 66th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

Read the detailed description

This clinical trial is phase I/II open label, multi-center study of rapcabtagene autoleucel.

The Phase I part of the study comprises three independent treatment arms:

  • Rapcabtagene autoleucel in combination with ibrutinib in adult CLL/SLL participants with SD or PR after at least 6 months of second or subsequent line ibrutinib therapy. As of 05-May-2021, this arm had completed enrollment.
  • Rapcabtagene autoleucel single agent in adult DLBCL participants having failed two or more lines of chemotherapy and either having progressed (or relapsed) after autologous HSCT or being ineligible for or not consenting to the procedure.
  • Rapcabtagene autoleucel single agent in adult relapsed/refractory ALL participants

The Phase II part of the study comprises two independent cohorts:

  • Rapcabtagene autoleucel single agent in adult 3L + DLBCL participants having failed two or more lines of chemoimmunotherapy and either having progressed (or relapsed) after autologous HSCT or being ineligible for or not consenting to the procedure. This is an extension of the Phase I r/r DLBCL treatment arm to support Phase II objectives
  • Rapcabtagene autoleucel single agent in newly diagnosed, adult 1L HR LBCL participants defined as IPI 3-5 and/or DH/TH disease who have completed 2 cycles of CIT and have a response of PR/SD (with a Deauville score of 4-5).

In the Phase I part of the trial, the 3L+ DLBCL and ALL arms consist of two parts: a dose escalation part to evaluate feasibility, characterize safety and identify the recommended dose (RD) of rapcabtagene autoleucel, and may be followed by a dose expansion part to further characterize safety, study rapcabtagene autoleucel cellular kinetics and assess preliminary antitumor activity. Once the RD of rapcabtagene autoleucel is determined for each arm, the corresponding expansion part may commence.

In the Phase II part of the trial, approximately 70 additional participants will be enrolled in a 3L+ DLBCL cohort treated at the recommended dose (RD). Including the 3L+ DLBCL participants who were treated at the RD from the Phase I part, it is planned to have in total a cohort of approximately 100 participants included in the primary efficacy analysis based on the efficacy analysis set. In addition, a separate cohort in 1LHR LBCL will be included, with approximately 50-60 participants planned for the primary efficacy analysis based on the efficacy analysis set.

Participants will be followed under the current treatment protocol for safety and efficacy within this trial for a minimum of 2 years before being transferred to the long-term follow-up trial. Once the study is complete, participants will be enrolled in a post-study long term follow-up for lentiviral vector safety for up to 15 years. This post-study long term follow-up for lentiviral vector safety will continue under a separate destination protocol.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma

Keywords

  • CAR-T
  • Ibrutinib
  • CLL
  • DLBCL
  • ALL
  • BLRM
  • YTB323
  • Rapcabtagene autoleucel
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status 0-1 for ALL and DLBCL
  • ECOG performance status 0-2 for 1L HR LBCL at screening
  • CLL or SLL diagnosis according to iwCLL criteria
  • CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or subsequent
  • DLBCL diagnosis by local histopathology
  • DLBCL after 2 or more lines of therapy, including hematopoietic stem cell transplantation (HSCT)
  • Refractory or relapsed CD19-positive ALL
  • ALL with morphologic disease in the bone marrow

    1L HR LBCL - Considered to be high-risk based on at least 1 of the following at diagnosis:

    • IPI score of 3, 4 or 5
    • MYC and BCL2 and/or BCL6 rearrangement (DH/TH lymphoma)
  • Participants must have received 2 cycles of frontline therapy for LBCL with R-CHOP or Pola-R-CHP or DA-EPOCH-R. Participants with DH/TH lymphoma must have received at least one cycle (the most recent) DA-EPOCH-R.
  • Participants must have a positive PET per Lugano classification (Deauville PET score of 4 or 5 and an overall response of PR/SD) after 2 cycles of frontline CIT. Note: Patient's with Deauville PET score of 5 and overall response of PD, or with Deauville PET score of 1, 2, or 3 and overall response of CR, are not eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  • Prior CD19-directed therapy
  • Prior administration of a genetically engineered cellular product
  • Prior HSCT
  • Richter's transformation

    • For 1L HR LBCL: Richter's transformation, Burkitt lymphoma, primary DLBCL of CNS, DLBCL associated with chronic inflammation, intravascular large B-cell lymphoma, ALK- positive large B-cell lymphoma, HHV8 positive LBCL, DLBCL leg type or EBV positive DLBCL, NOS.
  • Active CNS lymphoma

    • For 1L HR LBCL: Active or prior history CNS involvement by
  • Targeted small molecule or kinase inhibitor within 2 weeks from leukapheresis

Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    CLL/SLL

    Dose escalation of rapcabtagene autoleucel in combination with ibrutinib

    Biological: Rapcabtagene autoleucel single agent · Drug: Ibrutinib

  • Experimental
    3L+ DLBCL

    Dose escalation and expansion of rapcabtagene autoleucel single agent in 3L+ DLBCL

    Biological: Rapcabtagene autoleucel single agent

  • Experimental
    Adult ALL

    Dose escalation of rapcabtagene autoleucel single agent in adult ALL

    Biological: Rapcabtagene autoleucel single agent

  • Experimental
    1L HR LBCL

    Rapcabtagene autoleucel single agent in 1L HR LBCL

    Biological: Rapcabtagene autoleucel single agent

Interventions

  • BiologicalRapcabtagene autoleucel single agent

    Single infusion of rapcabtagene autoleucel

  • Tablets or capsules for oral daily use

06

What researchers measure

Primary outcomes

  1. Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only)

    Time frame: 28 days

  2. Phase 1: Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs

    Time frame: 24 months

  3. Phase 1: Tolerability: Ibrutinib dose modifications in the CLL/SLL arm

    Time frame: 24 months

  4. Phase 1: Manufacture success: Number of patients infused with planned target dose

    Time frame: 24 months

  5. Phase 2: Complete Response Rate (CRR) as assessed by local Investigator

    CRR defined as best overall response (BOR) of CR after rapcabtagene autoleucel infusion as per Lugano criteria for 3L+ Diffuse Large B-Cell Lymphoma (DLBCL) and 1L High Risk Large B-Cell (HR LBCL)

    Time frame: 24 months

Secondary outcomes

  1. Phase 1: Complete Response (CR)/Partial Response (CR) in CLL/SLL

    per international workshop on Chronic Lymphocytic Leukemia (iwCLL) response criteria

    Time frame: 24 months

  2. Phase 1: BOR of CR/PR per Lugano criteria in 3L+ DLBCL

    Time frame: 24 months

  3. Phase 1: Duration of response (DOR) in CLL/SLL and 3L+ DLBCL

    DOR as assessed by time from first achievement of CR/PR after rapcabtagene autoleucel infusion until first documented disease progression or death due to any cause

    Time frame: 24 months

  4. Phase 1: BOR in ALL as assessed by an Independent Review Committee (IRC)

    BOR of CR/CRi by 3 months after rapcabtagene autoleucel infusion as per IRC assessment.

    Time frame: month 3

  5. Phase 1: DOR in ALL as assessed by an Independent Review Committee

    DOR, defined as the time from achievement of CR or CRi to relapse or death due to any cause

    Time frame: 24 months

  6. Phase 1: EFS in ALL as assessed by an Independent Review Committee

    EFS, defined as the date from rapcabtagene autoleucel infusion to the earliest date of relapse after CR/CRi, treatment failure (defined as failure to achieve CR/CRi within 12 weeks of infusion), or death due to any cause

    Time frame: 24 months

  7. Phase 1: BOR in ALL as assessed by local Investigator

    BOR of CR/CRi

    Time frame: 24 months

  8. Phase 1: DOR in ALL as assessed by local Investigator

    DOR, defined as the time from achievement of CR or CRi to relapse or death due to any cause.

    Time frame: 24 months

  9. Phase 1: EFS in ALL as assessed by local Investigator

    EFS, defined as the date from rapcabtagene autoleucel infusion to the earliest date of relapse after CR/CRi, treatment failure (defined as failure to achieve CR/CRi within 12 weeks of infusion), or death due to any cause

    Time frame: 24 months

  10. Phase 1: Overall survival in adult ALL

    OS defined as time from the date of infusion to the date of death due to any reason

    Time frame: 24 months

  11. Phase 1: MRD negative status by flow cytometry in adult ALL

    Time frame: 24 months

  12. Phase 1: Quality of life in adult ALL patients enrolled in the expansion part by use of Electronic Patient Reported Outcomes (ePRO) as per EORTC QLQ-C30 questionnaire

    Time frame: 24 months

  13. Phase 1: Quality of life in adult ALL patients enrolled in the expansion part by use of Electronic Patient Reported Outcomes (ePRO) as per EQ-5D-3 questionnaire

    Time frame: 24 months

  14. Phase 1/2: Cellular kinetics

    CAR transgene levels by quantitative polymerase chain reaction (qPCR) in peripheral blood, bone marrow and lymph nodes

    Time frame: 24 months

  15. Phase 1/2: Immunogenicity

    Cellular and humoral responses to the CAR transgene

    Time frame: 24 months

  16. Phase 2: Overall response rate (ORR)

    ORR defined as BOR of CR/PR as per Lugano criteria in 3L+ DLBCL and 1L HR LBCL

    Time frame: 24 months

  17. Phase 2: Complete Response Rate (CRR)

    CRR at months 3, 6 in 3L+ DLBCL

    Time frame: months 3, 6

  18. Phase 2: Complete Response Rate (CRR)

    CRR at months 6, 12 in 1L HR LBCL

    Time frame: months 6, 12

  19. Phase 2: Duration of response (DOR)

    DOR defined as time from first CR/PR to first documented progression or death due to any cause in 3L+ DLBCL and 1L HR LBCL

    Time frame: 24 months

  20. Phase 2: Progression-free survival (PFS)

    PFS defined as time from rapcabtagene autoleucel infusion to first documented progression or death due to any cause in 3L+ DLBCL and 1L HR LBCL

    Time frame: 24 months

  21. Phase 2: Event-free survival (EFS)

    EFS defined as time from rapcabtagene autoleucel infusion to first documented progression, start of new anti-lymphoma therapy, biopsy-proven residual disease on or after month 6, or death due to any cause in 1L HR LBCL

    Time frame: 24 months

  22. Phase 2: Overall survival (OS)

    OS defined as time from date of rapcabtagene autoleucel infusion to date of death due to any cause in 3L+ DLBCL and 1L HR LBCL

    Time frame: 24 months

  23. Phase 2: Complete Response Rate (CRR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    CRR at months 6, 12 in 1L HR LBCL

    Time frame: months 6, 12

  24. Phase 2: Overall response rate (ORR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    ORR defined as BOR of CR/PR as per Lugano criteria 1L HR LBCL

    Time frame: 24 months

  25. Phase 2: Duration of response (DOR) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    DOR defined as time from first CR/PR to first documented progression or death due to any cause in 1L HR LBCL

    Time frame: 24 months

  26. Phase 2: Progression-free survival (PFS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    PFS defined as time from rapcabtagene autoleucel infusion to first documented progression or death due to any cause in 1L HR LBCL

    Time frame: 24 months

  27. Phase 2: Event-free survival (EFS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    EFS defined as time from rapcabtagene autoleucel infusion to first documented progression, start of new anti-lymphoma therapy, biopsy-proven residual disease on or after month 6, or death due to any cause in 1L HR LBCL

    Time frame: 24 months

  28. Phase 2: Overall survival (OS) in subgroups 1) IPI 4-5 or DH/TH and 2) IPI 3 and not DH/TH

    OS defined as time from date of rapcabtagene autoleucel infusion to date of death due to any cause in 1L HR LBCL

    Time frame: 24 months

  29. Phase 2: Manufacturing vein to door time

    Time from apheresis completion until return of rapcabtagene autoleucel product to the clinic or hospital

    Time frame: 24 months

07

Study locations

37 sites
  • University of California LA
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Stanford, California 94305-5826, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Uni of Chi Medi Ctr Hema and Onco
    Chicago, Illinois 60637, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Mass Gen Hosp Cancer Center
    Boston, Massachusetts 02114, United States
  • University of Pennsylvania Clinical
    Philadelphia, Pennsylvania 19104, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • St Davids South Austin Medical Ctr
    Austin, Texas 78704, United States
  • Uni Of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Sarah Cannon Research Institute
    San Antonio, Texas 78229, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138677, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Badalona, Barcelona 08916, Spain
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
  • Novartis Investigative Site
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Jun 2027, 96 months after the start.

Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 96 months is above that.

Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.

Completion moved once since we started tracking on Sep 25, 2026: May 2028 → Jul 2027, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 23, 2019
StartActual
Jun 26, 2019
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 24, 2027was May 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Sarah Cannon Research Institute · San Antonio, United States
Show 1 removed
  • Sarah Cannon Research Institute · Nashville, United States
Oct 29, 2026
Study completion
May 31, 2028→Jul 24, 2027
Oct 29, 2026
Enrollment
217→218
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    1 site added, 1 site removed
    Show site
    • Sarah Cannon Research Institute · San Antonio, United States
    Show 1 removed
    • Sarah Cannon Research Institute · Nashville, United States
    Study completion May 31, 2028→Jul 24, 2027
    Enrollment 217→218
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03960840
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jun 26, 2019
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 24, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion